Vion Pharmaceuticals, Inc.

Vion Pharmaceuticals, Inc.

File:Vion Pharmaceuticals Logo.gif
Former type	Public OTC BB: VIONQ.OB)
ISIN	🆔
Industry	Pharmaceuticals
Founded 📆	1992
Founder 👔
Defunct	2009 (2009)
Headquarters 🏙️	New Haven, Connecticut, United States
Area served 🗺️
Members
Number of employees
🌐 Website	www.vionpharm.com
📇 Address
📞 telephone

Vion Pharmaceuticals, Inc. was a New Haven, Connecticut based pharmaceutical company founded in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University.

Clinical development

Two anticancer agents, Onrigin (laromustine), formerly cloretazine (VNP40101M), and Triapine, a ribonucleotide reductase inhibitor similar to hydroxyurea, were in human clinical trials. A novel alkylating agent, Onrigin was evaluated in a Phase 2 trial in elderly de novo poor-risk acute myeloid leukemia (AML). In addition, several trials of Onrigin were conducted in elderly patients with AML and myelodysplastic syndrome (MDS) in combination with cytarabine, and in patients with brain tumors in combination with temozolomide.

Bankruptcy

After Onrigin was rejected by the Food and Drug Administration for an AML indication in 2009 due to an unfavorable risk-benefit profile, the company became defunct. The company declared bankruptcy in December 2009.

References

This article "Vion Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Vion Pharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• China PharmaHub Corp.
• Hayat Pharma Canada
• Lombart Instrument
• SmithKline Beckman
• Bertin (company)
• Inibsa
• Savage Laboratories

---